Inflammatix hopes to market an 18-gene panel that will be able to tell from a blood sample whether a hospitalized patient has a bacterial, viral, or no infection.
The test from Qiagen was able to identify young children with high interferon-gamma levels who later developed active disease.
Following validation, the approach, which uses a deep convolutional neural network trained with almost 130,000 clinical images, could be developed into a smartphone app to detect skin cancer early.
Stanford researchers showed that wearables could identify inflammation, insulin resistance, and the onset of infection.
Modeled on a children's toy, the device can separate plasma from whole blood in less than two minutes and costs $.20 to make.
The new assays — one targeting 17 genes and one targeting 77 genes — are based on the CAPP-Seq technology developed by Stanford University
The technologies will be added to ClearLight's portfolio for the three-dimensional interrogation and imaging of tissue samples.